MNG263
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.565
- E2F_TARGETS+0.442
- G2M_CHECKPOINT+0.374
- CHOLESTEROL_HOMEOSTASIS+0.293
- PANCREAS_BETA_CELLS+0.287
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- DNA_REPAIR+0.251
- MYC_TARGETS_V1+0.246
- MTORC1_SIGNALING+0.243
- MYC_TARGETS_V2+0.235
Top 10 suppressed
- TGF_BETA_SIGNALING-0.429
- UV_RESPONSE_DN-0.358
- ANDROGEN_RESPONSE-0.319
- IL6_JAK_STAT3_SIGNALING-0.296
- PROTEIN_SECRETION-0.288
- PI3K_AKT_MTOR_SIGNALING-0.249
- ANGIOGENESIS-0.241
- INFLAMMATORY_RESPONSE-0.227
- IL2_STAT5_SIGNALING-0.207
- HEDGEHOG_SIGNALING-0.206
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942959 | — | — | 0.808 |
| 2 | SRR11296848 | — | — | 0.797 |
| 3 | TCGA-UU-A93S-01A-21R-A41B-07 | — | C | 0.791 |
| 4 | MNG713 | — | — | 0.778 |
| 5 | MNG158 | — | — | 0.774 |
| 6 | TCGA-OR-A5JE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.773 |
| 7 | SRR8518230 | — | E | 0.773 |
| 8 | TCGA-Z7-A8R6-01A-11R-A41B-07 | — | B | 0.772 |
| 9 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.764 |
| 10 | FFAA0A2D-49B7-4491-9B22-C82CCF1501D0 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.565 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.442 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.374 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.293 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.287 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.251 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.246 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.243 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.235 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.215 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.149 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.134 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.132 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.131 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.122 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.113 | Idelalisib | — uncovered |
| MYOGENESIS | 0.109 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.108 | Inavolisib | — uncovered |